Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) – Investment analysts at William Blair lifted their FY2023 earnings per share estimates for Janux Therapeutics in a report released on Wednesday, November 8th. William Blair analyst M. Phipps now anticipates that the company will earn ($1.37) per share for the year, up from their prior estimate of ($1.58). The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.67) per share. William Blair also issued estimates for Janux Therapeutics’ Q4 2023 earnings at ($0.30) EPS, Q1 2024 earnings at ($0.31) EPS, Q2 2024 earnings at ($0.32) EPS, Q3 2024 earnings at ($0.33) EPS, Q4 2024 earnings at ($0.36) EPS, FY2024 earnings at ($1.31) EPS, FY2025 earnings at ($1.50) EPS, FY2026 earnings at ($1.79) EPS and FY2027 earnings at ($2.54) EPS.
JANX has been the subject of a number of other research reports. HC Wainwright reissued a “buy” rating and issued a $35.00 price target on shares of Janux Therapeutics in a report on Wednesday, August 9th. Wedbush reaffirmed an “outperform” rating and set a $24.00 target price on shares of Janux Therapeutics in a report on Wednesday, November 8th.
Janux Therapeutics Stock Performance
Shares of JANX opened at $6.04 on Monday. The company has a market capitalization of $278.87 million, a P/E ratio of -4.08 and a beta of 1.67. Janux Therapeutics has a one year low of $5.65 and a one year high of $23.64. The stock has a 50-day moving average price of $8.63 and a 200 day moving average price of $11.19.
Institutional Trading of Janux Therapeutics
Several hedge funds have recently made changes to their positions in JANX. BVF Inc. IL increased its position in Janux Therapeutics by 159.0% in the 2nd quarter. BVF Inc. IL now owns 4,106,945 shares of the company’s stock valued at $48,749,000 after acquiring an additional 2,521,268 shares during the period. EcoR1 Capital LLC increased its position in shares of Janux Therapeutics by 170.1% during the 1st quarter. EcoR1 Capital LLC now owns 3,838,486 shares of the company’s stock valued at $46,446,000 after purchasing an additional 2,417,167 shares during the period. BlackRock Inc. increased its position in shares of Janux Therapeutics by 15.2% during the 1st quarter. BlackRock Inc. now owns 1,161,721 shares of the company’s stock valued at $16,659,000 after purchasing an additional 153,460 shares during the period. UniSuper Management Pty Ltd acquired a new position in shares of Janux Therapeutics during the 2nd quarter valued at $1,649,000. Finally, Vanguard Group Inc. boosted its stake in shares of Janux Therapeutics by 17.1% during the 3rd quarter. Vanguard Group Inc. now owns 760,474 shares of the company’s stock worth $10,297,000 after acquiring an additional 110,834 shares in the last quarter. Institutional investors own 75.39% of the company’s stock.
About Janux Therapeutics
Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.
- Five stocks we like better than Janux Therapeutics
- Golden Cross Stocks: Pattern, Examples and Charts
- MarketBeat Week in Review – 11/6 – 11/10
- What is the Euro STOXX 50 Index?
- Data giants MongoDB and Snowflake just got upgraded
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.